Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$19.78M
• Dividend Yield: N/A
• Average Volume (3M): 36.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.40
• Revenue Growth: 95.76%
• EPS Growth: 22.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 131,886,760
• 10 Day Avg. Volume: 35,351
• 30 Day Avg. Volume: 36,089
• PEG Ratio: -0.38
• Price to Book (P/B): -5.82
• Price to Sales (P/S): 18.01
• P/FCF Ratio: -8.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.15 ▲(9.29% Upside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is primarily weighed down by weak financial performance (persistent large losses, negative equity, and ongoing cash burn). Technicals add caution with the stock trading below major moving averages and negative MACD, while valuation is difficult to justify with a negative P/E and no dividend yield data.

Positive Factors

Proprietary oral delivery platform

Rapid Dose’s proprietary quick-dissolve oral film is a durable competitive asset: it creates technical differentiation and supports an enablement/partnering business model across pharma and consumer health. Licensing and contract formulation can scale with limited capital intensity, enabling recurring revenue and higher long-term margins as adoption widens.

Improving revenue trend

Although base revenues are small, the company reports year-over-year revenue improvement and gains since 2023, signaling early commercial traction for its delivery platform. Sustained top-line growth provides the foundation for future operating leverage and the potential to absorb fixed costs, improving durability of the business model if growth continues.

Positive product gross margins

A roughly 30% gross margin indicates the delivery-format economics can generate meaningful margin per unit. With scale and better absorption of fixed costs, this margin profile supports a pathway to operational profitability, assuming the company can control SG&A and R&D spend and expand partner volumes over time.

Negative Factors

Deep and persistent losses

The company reports very large operating and net losses relative to sales, indicating current operations are not profitable and are structurally loss-making. Persistent negative margins constrain reinvestment capacity, require ongoing external funding, and raise execution risk for scaling the business model into sustained profitability.

Negative shareholders' equity and leverage

A deficit in shareholders' equity combined with notable debt creates a fragile capital structure. This reduces financial flexibility, increases the likelihood of dilution or costly financing, and elevates default or covenant risk, making it harder to execute long-term commercialization plans without recurrent external capital.

Ongoing cash burn and weak cash generation

Sustained negative operating and free cash flow indicate the business is not self-funding and relies on external capital to continue operations. Continued cash burn limits runway for R&D and commercialization, heightens refinancing risk, and can force strategic compromises that impair long-term competitive positioning.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

How the Company Makes Money

Rapid Dose Therapeutics Corp generates revenue primarily through the sale and licensing of its QuickStrip™ technology. The company partners with pharmaceutical, nutraceutical, and cannabis companies to incorporate QuickStrip™ into their product lines, earning income from manufacturing agreements and royalties. Additionally, Rapid Dose may engage in joint ventures or strategic collaborations to expand its application range and market penetration, further boosting its revenue streams.

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Financial statements indicate high risk: small TTM revenue ($2.78M) with modest growth, but very weak profitability (EBIT margin ~-111%, net margin ~-157%), negative shareholders’ equity (~-$6.65M) with meaningful debt (~$8.28M), and ongoing cash burn (TTM operating cash flow ~-$0.91M; free cash flow ~-$3.46M).

Income Statement

TTM (Trailing-Twelve-Months) revenue is small ($2.78M) with modest growth (+5.9%), but profitability remains very weak: gross margin is ~30% while operating results are deeply negative (EBIT margin ~-111%) and the company is still reporting large net losses (net margin ~-157%). Annual results show revenues have generally improved since 2023, but losses have persisted every year and remain sizable relative to sales, highlighting an ongoing challenge to scale profitably.

Balance Sheet

The balance sheet is strained, with negative shareholders’ equity in the most recent periods (TTM equity about -$6.65M) alongside meaningful debt (TTM total debt about $8.28M). Total assets are relatively low (~$3.79M TTM), and the combination of rising leverage and a deficit equity position increases financial risk and reduces flexibility, particularly if additional funding is needed.

Cash Flow

Cash generation remains weak with negative operating cash flow in TTM (about -$0.91M) and materially negative free cash flow (about -$3.46M), indicating ongoing cash burn. While free cash flow improved versus the prior period (positive growth rate), the company is still not self-funding operations, and the gap between cash outflows and profitability suggests continued reliance on external capital.

Breakdown	TTM	May 2024	May 2023	Nov 2022	Feb 2021	Feb 2020
Income Statement
Total Revenue	2.78M	2.09M	1.02M	718.30K	755.20K	101.50K
Gross Profit	829.37K	1.18M	563.41K	372.40K	699.85K	37.34K
EBITDA	-2.62M	-3.93M	-3.02M	-2.92M	-987.00K	-7.37M
Net Income	-4.37M	-5.40M	-4.31M	-3.81M	-1.80M	-7.96M
Balance Sheet
Total Assets	3.79M	1.63M	1.89M	2.25M	3.83M	4.29M
Cash, Cash Equivalents and Short-Term Investments	109.16K	20.72K	161.06K	27.59K	70.26K	3.47K
Total Debt	8.28M	2.61M	2.45M	1.61M	2.06M	1.22M
Total Liabilities	10.43M	6.84M	5.04M	4.92M	5.41M	4.44M
Stockholders Equity	-6.65M	-5.21M	-3.16M	-2.67M	-1.58M	-147.78K
Cash Flow
Free Cash Flow	-3.46M	-1.15M	-2.29M	-863.92K	-1.63M	-4.26M
Operating Cash Flow	-906.04K	-1.15M	-2.29M	-863.92K	-1.62M	-3.03M
Investing Cash Flow	-2.55M	-5.74K	0.00	0.00	-9.12K	530.46K
Financing Cash Flow	3.49M	1.01M	2.43M	856.53K	1.65M	1.24M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.14
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.00 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$16.23M	-2.00	―	―	-3.93%	-575.24%
BCT	44 Neutral	C$37.78M	-0.08	-409.25%	―	―	62.01%
HEM	44 Neutral	C$16.60M	-2.92	―	―	―	-24.89%
DOSE	41 Neutral	C$19.78M	-4.49	―	―	95.76%	22.56%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Therapeutics Lists on U.S. OTCQB to Broaden Investor Access

Rapid Dose Therapeutics Corp., a Canadian biotechnology company specializing in oral thin film drug delivery, is building its QuickStrip portfolio to serve pharmaceutical, nutraceutical and vaccine applications that require rapid and discreet administration. The company continues to list its shares on the Canadian Securities Exchange under the symbol DOSE, maintaining access to its home-market investor base.

The company has begun trading its common shares on the U.S. OTCQB Venture Market under the ticker RDTCF, expanding visibility and access for American healthcare and biotechnology investors. Management says the cross-border listing is intended to enhance liquidity, broaden market participation and support growth, partnerships and commercialization, reinforcing RDT’s positioning within the North American life sciences investment community.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Enters Brazil’s Medical Cannabis Market With QuickStrip Launch

Rapid Dose Therapeutics has launched its co-branded QuickStrip medical cannabis oral thin film in Brazil after securing regulatory approval from Brazil’s health regulator ANVISA for sublingual and buccal administration formats. The product, developed with Entourage Phytolab and distributed via U.S.-based partner Nexxions, positions RDT among the first to offer an oral dissolvable cannabis strip in Brazil’s fast-growing medical cannabis market.

The QuickStrip platform delivers precisely dosed cannabis via rapidly dissolving films designed to treat chronic pain, anxiety, sleep disorders, and neurological symptoms, offering a discreet, non-combustible alternative to oils and capsules. With Brazil’s recent regulatory reforms expanding cultivation permissions, treatment routes, and patient eligibility, and a market projected to grow strongly through 2034, RDT’s early entry and partnerships aim to establish it as a leading provider of consistent, high-quality cannabis therapies in Latin America’s largest healthcare market.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The interest payment in shares stems from an amended and restated note financing originally completed in 2023, under which the company extended the maturity of $3.08 million in promissory notes and associated warrants to November 30, 2026; the notes carry an 18% annual interest rate payable in stock at the Canadian Securities Exchange quarter-end closing price, a structure that preserves cash but dilutes existing shareholders while providing continued support from noteholders.

The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

Rapid Dose Therapeutics Corp. announced an extension of the maturity date for its secured convertible notes, originally set to mature on November 30, 2025, to November 30, 2026. This extension involves noteholders agreeing to new terms, including an increased interest rate from 12% to 18% per annum and an extension fee payable in common shares. The company also plans to issue common shares to satisfy accrued interest, with securities subject to a hold period. This move is part of a related party transaction involving company insiders and is exempt from certain regulatory requirements.